Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study

被引：0
|
作者：
Orbai, Ana-Maria [1 ]
Gellett, Amanda M. [2 ]
Kerr, Lisa [2 ]
Constantin, Arnaud [3 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Hop Pierre Paul Riquet, Toulouse, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2559
引用
收藏
页数：3
相关论文
共 50 条
  • [41] BIMEKIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Thaci, Diamant
    Gottlieb, Alice B.
    Asahina, Akihiko
    Lebwohl, Mark
    McInnes, Iain B.
    Warren, Richard
    Boehncke, Wolf-Henning
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Merola, Joseph F.
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [42] IXEKIZUMAB PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: TWO YEAR RESULTS FROM A PHASE 3 TRIAL
    Helliwell, P.
    Lespessailles, E.
    Shuler, C. L.
    Mallbris, L.
    Erickson, J.
    Fleischmann, R.
    Moyano, Sebastian
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S159 - S159
  • [43] Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two Year Results from a Phase 3 Trial
    Helliwell, Philip S.
    Lespessailles, Eric
    Shuler, Catherine
    Mallbris, Lotus
    Erickson, Janelle
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [44] Evaluation of Efficacy and Safety After Switching to Generic Fingolimod in Patients with Multiple Sclerosis: A Two-Year Follow-Up Study
    Moreno Torres, Irene
    Orviz, Aida
    Nystrom Hernandez, Anna Lena
    De la Fuente, Soraya
    Arrieta Loitegui, Maria
    Hernandez Segurado, Marta
    Becares Martinez, Javier
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1083 - 1083
  • [45] IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR-INHIBITORS
    Kavanaugh, A.
    Marzo-Ortega, H.
    Vender, R.
    Birt, J.
    Adams, D.
    Benichou, O.
    Lin, C-Y
    Nash, P.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 39 - 40
  • [46] Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
    Kavanaugh, Arthur
    Marzo-Ortega, Helena
    Vender, Ronald
    Birt, Julie
    Adams, David
    Benichou, Olivier
    Lin, Chen-Yen
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [47] Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
    Combe, Bernard
    Nash, Peter
    Adams, David
    Kerr, Lisa
    Benichou, Olivier
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [48] Five year follow-up: Efficacy and safety of leflunomide (LEF) in patients with active rheumatoid arthritis (RA).
    Kalden, J
    Schattenkirchner, M
    Sorensen, H
    Emery, P
    Deighton, C
    Rozman, B
    Breedveld, F
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S173 - S173
  • [49] TWO-YEAR TREATMENT OF PSORIATIC ARTHRITIS WITH BIOLOGICAL THERAPY: A REGISTRY-BASED LONGITUDINAL FOLLOW-UP
    Virkki, L.
    Tuompo, R.
    Ilva, K.
    Vasala, M.
    Malmi, T.
    Kankaanpa, E.
    Arstila, L.
    Lahteenmaki, J.
    Peltomaa, R.
    Aaltonen, K.
    Nordstrom, D.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2011, 40 (03) : 245 - 245
  • [50] Efficacy of Adalimumab in active Psoriatic Arthritis and inadequate Response to up to three Anti-TNF Pre-Therapies
    Koehm, M.
    Behrens, F.
    Thaci, D.
    Krummel-Lorenz, B.
    Greger, G.
    Wittig, B.
    Burkhardt, H.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 124 - 124
12345